Tags

Type your tag names separated by a space and hit enter

Isoliquiritigenin attenuates diabetic cardiomyopathy via inhibition of hyperglycemia-induced inflammatory response and oxidative stress.
Phytomedicine. 2020 Nov; 78:153319.P

Abstract

BACKGROUND

Inflammation and oxidative stress play essential roles in the occurrence and progression of diabetic cardiomyopathy (DCM). Isoliquiritigenin (ISL), a natural chalcone, exhibits strong anti-inflammatory and antioxidant activities.

HYPOTHESIS/PURPOSE

In this study, we aimed to investigate the protective effects of ISL on DCM using high glucose (HG)-challenged cultured cardiomyocytes and streptozotocin (STZ)-induced diabetic mice.

STUDY DESIGN AND METHODS

Embryonic rat heart-derived H9c2 cells challenged with a high concentration of glucose were used to evaluate the anti-inflammatory and antioxidant effects of ISL. STZ-induced diabetic mice were used to study the effects of ISL in DCM in vivo. Furthermore, cardiac fibrosis, hypertrophy, and apoptosis were explored both in vitro and in vivo.

RESULTS

ISL effectively inhibited HG-induced hypertrophy, fibrosis, and apoptosis probably by alleviating the inflammatory response and oxidative stress in H9c2 cells. Results from in vivo experiments showed that ISL exhibited anti-inflammatory and antioxidant stress activities that were characterized by the attenuation of cardiac hypertrophy, fibrosis, and apoptosis, which resulted in the maintenance of cardiac function. The protective effects of ISL against inflammation and oxidative stress were mediated by the inhibition of mitogen-activated protein kinases (MAPKs) and induction of nuclear factor-erythroid 2 related factor 2 (Nrf2) signaling pathway, respectively.

CONCLUSION

Our results provided compelling evidence that ISL, by virtue of neutralizing excessive inflammatory response and oxidative stress, could be a promising agent in the treatment of DCM. Targeting the MAPKs and Nrf2 signaling pathway might be an effective therapeutic strategy for the prevention and treatment of DCM.

Authors+Show Affiliations

Department of Endocrinology, the First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China; Department of Endocrinology, Jiangshan People's Hospital, Jiangshan, Zhejiang, China.Department of Endocrinology, the First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.Department of Rehabilitation, Children's Hospital of Nanjing Medical University, Nanjing, China.Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.Department of Endocrinology, the First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.Department of Cardiology, the Second Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.Department of Cardiology, the First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.Department of Endocrinology, the First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.Department of Cardiology, the First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China. Electronic address: 2855930357@qq.com.Department of Endocrinology, the First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China. Electronic address: chenzimiao96@163.com.Department of Endocrinology, the First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China; Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China. Electronic address: chasecx@126.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32950951

Citation

Gu, Xuemei, et al. "Isoliquiritigenin Attenuates Diabetic Cardiomyopathy Via Inhibition of Hyperglycemia-induced Inflammatory Response and Oxidative Stress." Phytomedicine : International Journal of Phytotherapy and Phytopharmacology, vol. 78, 2020, p. 153319.
Gu X, Shi Y, Chen X, et al. Isoliquiritigenin attenuates diabetic cardiomyopathy via inhibition of hyperglycemia-induced inflammatory response and oxidative stress. Phytomedicine. 2020;78:153319.
Gu, X., Shi, Y., Chen, X., Sun, Z., Luo, W., Hu, X., Jin, G., You, S., Qian, Y., Wu, W., Liang, G., Wu, G., Chen, Z., & Chen, X. (2020). Isoliquiritigenin attenuates diabetic cardiomyopathy via inhibition of hyperglycemia-induced inflammatory response and oxidative stress. Phytomedicine : International Journal of Phytotherapy and Phytopharmacology, 78, 153319. https://doi.org/10.1016/j.phymed.2020.153319
Gu X, et al. Isoliquiritigenin Attenuates Diabetic Cardiomyopathy Via Inhibition of Hyperglycemia-induced Inflammatory Response and Oxidative Stress. Phytomedicine. 2020;78:153319. PubMed PMID: 32950951.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Isoliquiritigenin attenuates diabetic cardiomyopathy via inhibition of hyperglycemia-induced inflammatory response and oxidative stress. AU - Gu,Xuemei, AU - Shi,Yujuan, AU - Chen,Xiaojun, AU - Sun,Zijia, AU - Luo,Wu, AU - Hu,Xiang, AU - Jin,Ge, AU - You,Shengban, AU - Qian,Yuanyuan, AU - Wu,Wenjun, AU - Liang,Guang, AU - Wu,Gaojun, AU - Chen,Zimiao, AU - Chen,Xiong, Y1 - 2020/09/01/ PY - 2020/04/01/received PY - 2020/08/28/revised PY - 2020/08/31/accepted PY - 2020/9/21/pubmed PY - 2020/12/1/medline PY - 2020/9/20/entrez KW - Cardiomyopathy KW - Diabetes KW - Inflammation KW - Isoliquiritigenin KW - Oxidative stress SP - 153319 EP - 153319 JF - Phytomedicine : international journal of phytotherapy and phytopharmacology JO - Phytomedicine VL - 78 N2 - BACKGROUND: Inflammation and oxidative stress play essential roles in the occurrence and progression of diabetic cardiomyopathy (DCM). Isoliquiritigenin (ISL), a natural chalcone, exhibits strong anti-inflammatory and antioxidant activities. HYPOTHESIS/PURPOSE: In this study, we aimed to investigate the protective effects of ISL on DCM using high glucose (HG)-challenged cultured cardiomyocytes and streptozotocin (STZ)-induced diabetic mice. STUDY DESIGN AND METHODS: Embryonic rat heart-derived H9c2 cells challenged with a high concentration of glucose were used to evaluate the anti-inflammatory and antioxidant effects of ISL. STZ-induced diabetic mice were used to study the effects of ISL in DCM in vivo. Furthermore, cardiac fibrosis, hypertrophy, and apoptosis were explored both in vitro and in vivo. RESULTS: ISL effectively inhibited HG-induced hypertrophy, fibrosis, and apoptosis probably by alleviating the inflammatory response and oxidative stress in H9c2 cells. Results from in vivo experiments showed that ISL exhibited anti-inflammatory and antioxidant stress activities that were characterized by the attenuation of cardiac hypertrophy, fibrosis, and apoptosis, which resulted in the maintenance of cardiac function. The protective effects of ISL against inflammation and oxidative stress were mediated by the inhibition of mitogen-activated protein kinases (MAPKs) and induction of nuclear factor-erythroid 2 related factor 2 (Nrf2) signaling pathway, respectively. CONCLUSION: Our results provided compelling evidence that ISL, by virtue of neutralizing excessive inflammatory response and oxidative stress, could be a promising agent in the treatment of DCM. Targeting the MAPKs and Nrf2 signaling pathway might be an effective therapeutic strategy for the prevention and treatment of DCM. SN - 1618-095X UR - https://www.unboundmedicine.com/medline/citation/32950951/Isoliquiritigenin_attenuates_diabetic_cardiomyopathy_via_inhibition_of_hyperglycemia_induced_inflammatory_response_and_oxidative_stress_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0944-7113(20)30151-3 DB - PRIME DP - Unbound Medicine ER -